H1B11 12
Alternative Names: anti-G-CSF antibody candidate - ME Therapeutics; h1B11-12Latest Information Update: 06 Mar 2024
Price :
$50 *
At a glance
- Originator ME Therapeutics
- Developer ME Therapeutics; University of British Columbia
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Dec 2023 ME Therapeutics files for patent protection for composition and use of anti-G-CSF antibody candidate in USA, Europe and Canada before December 2023
- 05 Dec 2023 Preclinical trials in Cancer in Canada (Parenteral) before December 2023
- 05 Dec 2023 ME Therapeutics announces intention to submit IND for Cancer